Status:
COMPLETED
Evolution of Pain From Herpes Zoster
Lead Sponsor:
University of California, San Francisco
Conditions:
Post-Herpetic Neuralgia
Acute Herpes Zoster
Eligibility:
All Genders
50+ years
Brief Summary
Evolution of pain and neural injury will be evaluated at 2 years or longer after the onset of AHZ by multiple measures. Assessments at 2 years or longer will be compared to those collected during the ...
Detailed Description
Pain, nerve trunk inflammation, and neuronal injury are hallmarks of acute herpes zoster (AHZ). We hypothesize that the development of post-herpetic neuralgia (PHN) strongly depends on two factors: 1)...
Eligibility Criteria
Inclusion
- Males and females aged 50 or older and in stable general health.
- Able and willing to provide written informed consent.
- Able to understand and follow the instructions of the investigator, including the pain intensity rating scales.
- Subjects must have an acute outbreak of cervical, thoracic or lumbosacral HZ with unilateral skin rash and pain; the diagnosis will be based on physical examination and review of available medical records confirming the outbreak.
- The outbreak of herpes zoster must have occurred less than 6 weeks prior to study entry.
- PHN pain must be of at least moderate severity, defined as self-report of average pain level of 20 mm on a 100 mm visual analog scale.
Exclusion
- The AHZ outbreak is complicated by stroke or myelopathy.
- Patients with facial or cranial AHZ.
- Patients with signs of spinal cord or brainstem injury from HZ.
- Patients who are considered unreliable as to study compliance or adherence to scheduled appointments as determined by the Investigators.
- Patients, who are undergoing active treatment for cancer, are infected with the Human Immunodeficiency Virus, or are being acutely and intensively immunosuppressed following a transplantation procedure.
- Bleeding disorders.
- Patients with known skin pathology.
- Use of topical steroids, capsaicin, local anesthetics or topical aspirin/NSAID preparations within two weeks of the study sessions.
- Another pain problem of equal or greater severity than AHZ.
- Allergy or idiosyncratic reaction to lidocaine or capsaicin.
- Neurological dysfunction or psychiatric disorder severe enough to interfere with assessment of pain and sensory systems.
- Has received neuroablative nerve blocks or neurosurgical procedures for AHZ pain prior to entering the study.
- Patients who are unable to read or speak English.
- Those, in the opinion of the investigator, who are unlikely to comply with the study protocol or who are unsuitable for any other reason.
Key Trial Info
Start Date :
November 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00305357
Start Date
November 1 2001
End Date
December 1 2006
Last Update
May 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF
San Francisco, California, United States, 94115